Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...
Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...
Over the last few days, UpScrolled went from a relatively unknown app to the top of the App Store, as users flocked away from TikTok. Here are the details. A few days ago, the years-long saga ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...
Abstract: Ensemble feature selection combines feature subsets with diversity, potentially providing a better approximation of the optimal feature subset. While extensive research has focused on ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
According to the American Cancer Society, colorectal cancer is the second leading cause of cancer death. Enrichment of regulatory T cells (T-regs) in solid cancers is generally associated with poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results